IP Library Granted Patent US 10,556,858
Granted Patent B2
US 10,556,858 · App. 16/115,028 · Granted Feb 11, 2020

Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17

Inventors: Eric Anderson (Southlake, TX); Xin Jiang (Coppell, TX); Melean Visnick (Irving, TX)
Assignee: REATA PHARMACEUTICALS, INC.
C07C255/47C07C271/24C07C275/26C07C275/34C07C311/07C07C311/09C07D209/56C07D211/44C07D231/12C07D261/08C07D295/195C07D307/20C07D487/08C07J63/008C07C2603/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,556,858
App. No.
16/115,028
Granted
Feb 11, 2020
Kind
B2
Abstract

This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Claims (46)

1. A method of making a first compound defined as:

wherein:

R 12 is OR d , or NR d R e , wherein:

R d is hydrogen; or

alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups;

R e is alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups; or

R d and R e are taken together and are -alkanediyl (C≤8) -, substituted -alkanediyl (C≤8) -, -alkenediyl (C≤8) -, substituted -alkenediyl (C≤8) -, or —N═CHCH═CH—;

wherein the first step of the synthesis comprises modification of the C-17 isocyanate group of the following compound:

2. The method of claim 1 , wherein the first compound is further defined as:

wherein:

R 12 is OR d , or NR d R e , wherein:

R d is hydrogen; or

alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups;

R e is alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups; or

R d and R e are taken together and are -alkanediyl (C≤8) -, substituted -alkanediyl (C≤8) -, -alkenediyl (C≤8) -, substituted -alkenediyl (C≤8) -, or —N═CHCH═CH—.

3. The method of claim 2 , wherein R d is hydrogen.

4. The method of claim 2 , wherein R d is alkyl (C≤8) or substituted alkyl (C≤8) .

5. The method of claim 2 , wherein R d is aryl (C≤8) or substituted aryl (C≤8) .

6. The method of claim 2 , wherein R e is alkyl (C≤8) or substituted alkyl (C≤8) .

7. The method of claim 2 , where R d and R e are taken together and are -alkanediyl (C≤8) - or substituted -alkanediyl (C≤8) -.

8. The method of claim 2 , where R d and R e are taken together and are —N═CHCH═CH—.

9. The method of claim 1 , wherein the first compound is further defined as:

wherein:

R 12 is OR d , or NR d R e , wherein:

R d is hydrogen; or

alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups;

R e is alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups; or

R d and R e are taken together and are -alkanediyl (C≤8) -, substituted -alkanediyl (C≤8) -, -alkenediyl (C≤8) -, substituted -alkenediyl (C≤8) -, or —N═CHCH═CH—.

10. The method of claim 9 , wherein R d is hydrogen.

11. The method of claim 9 , wherein R d is alkyl (C≤8) or substituted alkyl (C≤8) .

12. The method of claim 9 , wherein R d is aryl (C≤8) or substituted aryl (C≤8) .

13. The method of claim 9 , wherein R e is alkyl (C≤8) or substituted alkyl (C≤8) .

14. The method of claim 9 , where R d and R e are taken together and are -alkanediyl (C≤8) - or substituted -alkanediyl (C≤8) -.

15. The method of claim 9 , where R d and R e are taken together and are —N═CHCH═CH—.

16. The method of claim 1 , wherein the modification comprises reacting the following compound:

with a reagent of the formula HOR d , or HNR d R e , wherein:

R d is hydrogen; or

alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups;

R e is alkyl (C≤8) , alkenyl (C≤8) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤8) , heteroaralkyl (C≤8) , or a substituted version of any of these groups; or

R d and R e are taken together and are -alkanediyl (C≤8) -, substituted -alkanediyl (C≤8) -, -alkenediyl (C≤8) -, substituted -alkenediyl (C≤8) -, or —N═CHCH═CH—.

17. The method of claim 1 , wherein the modification is conducted in the absence of a solvent (i.e. neat).

18. The method of claim 1 , wherein the modification is conducted in a medium comprising a solvent.

19. The method of claim 18 , wherein the solvent is tetrahydrofuran, benzene, or dichloromethane.

20. The method of claim 1 , wherein the modification is conducted in the presence of a base.

21. The method of claim 20 , wherein the base is NEt 3 or NaH.

22. The method of claim 1 , wherein the first compound is further defined as:

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2022
From: REATA PHARMACEUTICALS, INC.
To: REATA PHARMACEUTICALS HOLDINGS, LLC
Reel/Frame 058639/0138 →
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 053034/0018 →
SECURITY INTEREST Recorded Oct 9, 2019
From: REATA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050670/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: ANDERSON, ERIC; JIANG, XIN; VISNICK, MELEAN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 046734/0001 →
Continuity (8)
Continuation 15615393 · Jun 6, 2017
Continuation 14753297 · Jun 29, 2015
Continuation 13861208 · Apr 11, 2013
Continuation 13356455 · Jan 23, 2012
Continuation 12426778 · Apr 20, 2009
Provisional Application 61111269 · Nov 4, 2008
Provisional Application 61046342 · Apr 18, 2008
Related Publication 20190119202A1 · Apr 25, 2019
Cited By (4)
US 12,344,631 US 12,358,866 US 12,384,815 US 12,545,701